Published in Cancer Weekly, December 14th, 2004
Revenues for the third-quarter 2004 were approximately $143,000 versus $258,000 for the comparable period a year ago. The company reported a net loss for the third quarter of approximately $3.1 million, or $0.09 per share. This compares with a net loss of approximately $4.6 million, or $0.15 per share for the same period last year.
For the 9 months ending September 30, 2004, revenues were approximately $380,000 versus $1.1 million for 2003....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.